<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id>
      <journal-title-group>
        <journal-title>Einstein</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1679-4508</issn>
      <issn pub-type="epub">2317-6385</issn>
      <publisher>
        <publisher-name>Instituto de Ensino e Pesquisa Albert Einstein</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25517085</article-id>
      <article-id pub-id-type="pmc">4946818</article-id>
      <article-id pub-id-type="publisher-id">S1679-45082014RC2975</article-id>
      <article-id pub-id-type="doi">10.1590/S1679-45082014RC2975</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Small cell carcinoma of the bladder</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Calado</surname>
            <given-names>Bruno Nagel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maron</surname>
            <given-names>Paulo Eduardo Goulart</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vedovato</surname>
            <given-names>Bruno C&#xE9;sar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barrese</surname>
            <given-names>Tomas Zecchini</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>Roni de Carvalho</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Perez</surname>
            <given-names>Marjo Deninson Cardenuto</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Faculdade de Ci&#xEA;ncias M&#xE9;dicas, Santa Casa de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil.</aff>
      <aff id="aff2"><label>2</label>Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil.</aff>
      <author-notes>
        <corresp id="c01"><label>Corresponding author</label>: Bruno Nagel Calado &#x2212; Santa Casa de S&#xE3;o Paulo, Rua Dr. Cesario Motta Jr, 112 &#x2212; Vila Buarque &#x2212; Zip code: 01221-020 &#x2212; S&#xE3;o Paulo, SP, Brazil &#x2212; Phone: (55 11) 2176-7000 E-mail:<email>caladobnc@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Mar</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Mar</season>
        <year>2015</year>
      </pub-date>
      <volume>13</volume>
      <issue>1</issue>
      <fpage>114</fpage>
      <lpage>116</lpage>
      <history>
        <date date-type="received">
          <day>3</day>
          <month>10</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Small cell carcinoma of the urinary bladder is an extremely aggressive and rare tumor. Even though small cell carcinoma most commonly arises from the lungs there are several reports of small cell carcinoma in extrapulmonary sites. Due to its low frequency there is no well-established management for this disease. We report the case of a 61 year-old man with small cell carcinoma of the bladder who underwent radical cystectomy following neoadjuvant chemotherapy. We also reviewed the literature for the optimal treatment strategy.</p>
      </abstract>
      <kwd-group>
        <kwd>Urinary bladder neoplasms/drug therapy</kwd>
        <kwd>Carcinoma</kwd>
        <kwd>small cell/drug therapy</kwd>
        <kwd>Cystectomy/methods</kwd>
        <kwd>Case reports</kwd>
      </kwd-group>
      <counts>
        <fig-count count="6"/>
        <ref-count count="11"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Small cell carcinoma of the bladder is a very rare and aggressive histological subtype, and accounts for less than 1% of all bladder tumors.<sup>(<xref rid="B1" ref-type="bibr">1</xref>) </sup>Its management is challenging because it presents in the same way of other more frequent histological types, but with a high metastatic power. The diagnosis demands that the pathologist be suspicious and accurate in the analysis of the fragments of a transurethral bladder resection (TUR). Multimodal treatment, including radical cystectomy, chemotherapy and radiation therapy should be initiated as soon as possible for a chance of cure and to improve survival.<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup> This kind of carcinoma presents metastasis and has a poor prognosis.</p>
      <p>In the present article we report a case of a male patient with small cell carcinoma of the bladder and the development of the condition, and we aim to show the most current management of this tumor, which has no consensus for treatment in the international literature for being extremely rare.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Patient JHC, male, 61 years old, came to the medical service with a complaint of hematuria and hypogastric pain for one year. The urinary tract ultrasound revealed an intravesical tumor, and he was submitted to bladder TUR, with a conclusive report for small cell carcinoma of the bladder. Faced with the diagnosis, the attending team chose to perform chemotherapy (received four sessions of cisplatin, gemcitabine and paclitaxel) (<xref ref-type="fig" rid="f01">Figure 1</xref>).</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Field with the presence of multiple mitoses, salt-and-pepper nuclei</title></caption><graphic xlink:href="1679-4508-eins-13-1-114-gf01"/></fig>
</p>
      <p>When referred to our service, he was submitted to thorax and abdomen computerized tomography (CT) that showed a 6.2x6.0x5.5cm neoplasm on the left anterolateral wall of the bladder, suggesting invasion of the prostatic urethra. No lymph nodes were affected and there were no metastatic lesions at other sites.</p>
      <p>The patent was then submitted to radical cystectomy, with a Bricker ileal derivation procedure, performed uneventfully, lasting 5 hours, with no need for blood transfusion. It is important to underscore that the time between the last chemotherapy and surgery was 2 months.</p>
      <p>The pathology report of the surgical specimen proved small cell carcinoma of the bladder with extravesical extension, perineural and vascular infiltration, and one lymph node affected (left obturator) out of 16 dissected. Free margins. Final staging T3bN1.</p>
      <p>During the post-operative period, the patient had pneumonia, was on antibiotics and was discharged 29 days after surgery. There were no surgical events. He was referred to oncology to discuss adjuvant therapy which was not initiated, because the patient died 4 months after surgery due to pulmonary thromboembolism (<xref ref-type="fig" rid="f02">Figure 2</xref>).</p>
      <p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>General overview of the tumor</title></caption><graphic xlink:href="1679-4508-eins-13-1-114-gf02"/></fig>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The first report of small cell carcinoma of the bladder was made in 1981 by Cramer et al. Since then, approximately 600 cases were registered in the international literature.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup> It is characterized by its high aggressiveness and poor prognosis, and by the development of metastic disease in about 67% of patients.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
      <p>The small cell carcinoma of the bladder usually affects individuals of the same age, sex and presents the same symptoms and morphology of urothelial carcinoma. That is why it is a diagnostic challenge, depending only on the skills of the pathologist to differentiate it from urothelial carcinoma, which beside the factors already mentioned, has the same radiological aspect of small cell carcinoma of the bladder. There is no consensus as to treatment, because it is an uncommon condition. Thus, recommendations are based on retrospective studies, reports of individual cases, and protocols for small cell lung carcinoma.</p>
      <p>Frequently, it presents with mixed histology.<sup>(<xref rid="B5" ref-type="bibr">5</xref>) </sup>Molecular studies show a common origin for small cell carcinoma of the bladder and urothelial carcinoma, when coexisting. However, management should be different, since it frequently presents metastases and has a poor prognosis. The pathological diagnosis of this kind of tumor is challenging and requires that the pathologist use immunohistochemical techniques for histological confirmation. As they are histologically identical, the World Health Organization standardization for small cell lung carcinoma is used. It comprises the following criteria for diagnosis of small cell carcinoma of the bladder: presence of group of small cells with scarce cytoplasm, few organelles, &#x201C;salt and pepper&#x201D; chromatin and high rate of mitoses (&gt;10 mitoses/10 high power fields).<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
      <p>On immunohistochemistry, these tumors express quite an amount of neurospecific enolase, chromogranin, synaptophysin and N-CAM (CD-56). The presence of one or more markers allows to establish the diagnosis of neuroendocrine tumor. Pathological staging is based on the consensus for urothelial carcinoma of the bladder (<xref ref-type="fig" rid="f03">Figure 3</xref>).<sup>(<xref rid="B4" ref-type="bibr">4</xref>) </sup>
</p>
      <p>
<fig id="f03" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Marker CD-56 that characterizes neuroendocrine tumors</title></caption><graphic xlink:href="1679-4508-eins-13-1-114-gf03"/></fig>
</p>
      <p>Isolated therapies &#x2013; whether TUR, partial cystectomy or radiation therapy &#x2013; present benefit only in special cases of initial stage disease. Radical cystectomy is considered the best method to eliminate small cell carcinoma of the bladder completely, but it alone is believed to only change survival in stage I and II tumors.<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup> Cheng et al. reviewed 64 cases and concluded that in patients submitted to radical surgery compared to those treated with combined treatment (whether only chemotherapy or radiation therapy or both as adjuvant), there was no increase in survival.<sup>(<xref rid="B7" ref-type="bibr">7</xref>)</sup> In contrast, chemotherapy adjuvant to radical cystectomy resulted in a favorable prognosis in other studies, including meta-analyses.<sup>(<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>)</sup>
</p>
      <p>Another alternative is neoadjuvant chemotherapy, recommended by the MD Anderson Cancer Center, which reported a 5-year disease free survival in 36% of the group submitted to radical cystectomy alone and of 78% in the group submitted to chemotherapy neoadjuvant to surgery.<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup> Similarly, neo adjuvant radiation therapy has also shown itself efficient.</p>
      <p>On the other hand, a Canadian group reported ten patients with pT3-T4, N0 lesions with chemotherapy, attaining complete remission in nine of them. The 2-year survival rate for this group was 70% and, 44% in 5 years.<sup>(<xref rid="B10" ref-type="bibr">10</xref>)</sup> Another similar series reported four patients treated with chemotherapy followed by radiation therapy who survived 27 to 60 months. The advantage of this treatment is sparing the organ. Therefore, it is a less invasive treatment when compared to radical surgery, which is related to important rates of morbidity and mortality.<sup>(<xref rid="B11" ref-type="bibr">11</xref>)</sup>
</p>
      <p>Patients with metastatic disease should receive systematic chemotherapy, and the most common treatment regimens are platinum-based (cisplatin and etoposide, carboplatin, etoposide and cyclophosphamide) (<xref ref-type="fig" rid="f02">Figure 2</xref>).<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
    </sec>
    <sec sec-type="conclusions">
      <title>CONCLUSION</title>
      <p>Given the extremely aggressive and rare disease, little is known about pathogenesis and molecular biology. Data on the ideal approach for this kind of tumor are scarce, showing the importance of reporting such cases and, in this way, defining the best diagnostic and treatment methods.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Zhao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Flynn</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Small cell carcinoma of the urinary bladder: a rare, aggressive neuroendocrine malignancy</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>2012</year>
          <volume>136</volume>
          <issue>11</issue>
          <fpage>1451</fpage>
          <lpage>1459</lpage>
          <pub-id pub-id-type="pmid">23106592</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Shahab</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Extrapulmonary small cell carcinoma of the bladder</article-title>
          <source>Semin Oncol</source>
          <year>2007</year>
          <volume>34</volume>
          <issue>1</issue>
          <fpage>15</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">17270661</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Church</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Bahl</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Clinical review - small cell carcinoma of the bladder</article-title>
          <source>Cancer Treat Rev</source>
          <year>2006</year>
          <volume>32</volume>
          <issue>8</issue>
          <fpage>588</fpage>
          <lpage>593</lpage>
          <pub-id pub-id-type="pmid">17008012</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Cramer</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Aikawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cebelin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Neurosecretory granules in small cell invasive carcinoma of the urinary bladder</article-title>
          <source>Cancer</source>
          <year>1981</year>
          <volume>47</volume>
          <issue>4</issue>
          <fpage>724</fpage>
          <lpage>730</lpage>
          <pub-id pub-id-type="pmid">6261916</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Mazzucchelli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Morichetti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lopez-Beltran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scarpelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kirkali</surname>
              <given-names>Z</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Neuroendocrine tumours of the urinary system and male genital organs: clinical significance</article-title>
          <source>BJU Int</source>
          <year>2009</year>
          <volume>103</volume>
          <issue>11</issue>
          <fpage>1464</fpage>
          <lpage>1470</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">19254281</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Choong</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Quevedo</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Small cell carcinoma of the urinary bladder. The Mayo Clinic experience</article-title>
          <source>Cancer</source>
          <year>2005</year>
          <volume>103</volume>
          <issue>6</issue>
          <fpage>1172</fpage>
          <lpage>1178</lpage>
          <pub-id pub-id-type="pmid">15700264</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Cheng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>CX</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>XJ</given-names>
            </name>
            <name>
              <surname>Lopez-Beltran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>MacLennan</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients</article-title>
          <source>Cancer</source>
          <year>2004</year>
          <volume>101</volume>
          <issue>5</issue>
          <fpage>957</fpage>
          <lpage>962</lpage>
          <pub-id pub-id-type="pmid">15329903</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Mackey</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Au</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Hugh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Venner</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival</article-title>
          <source>J Urol</source>
          <year>1998</year>
          <volume>159</volume>
          <issue>5</issue>
          <fpage>1624</fpage>
          <lpage>1629</lpage>
          <pub-id pub-id-type="pmid">9554367</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Siefker-Radtke</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Dinney</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Abrahams</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Moran</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Pisters</surname>
              <given-names>LL</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience</article-title>
          <source>J Urol</source>
          <year>2004</year>
          <volume>172</volume>
          <issue>2</issue>
          <fpage>481</fpage>
          <lpage>484</lpage>
          <pub-id pub-id-type="pmid">15247709</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Lohrisch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Pickles</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation</article-title>
          <source>Cancer</source>
          <year>1999</year>
          <volume>86</volume>
          <issue>11</issue>
          <fpage>2346</fpage>
          <lpage>2352</lpage>
          <pub-id pub-id-type="pmid">10590377</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Bast&#xFA;s</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Caballero</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Gonz&#xE1;lez</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Borrat</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Casalots</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gomez de Segura</surname>
              <given-names>G</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Small cell carcinoma of the urinary bladder treated with chemotherapy and radiotherapy: results in five cases</article-title>
          <source>Eur Urol</source>
          <year>1999</year>
          <volume>35</volume>
          <issue>4</issue>
          <fpage>323</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="pmid">10087396</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="TRpt" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato De Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Carcinoma de c&#xE9;lulas pequenas de bexiga</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Calado</surname>
            <given-names>Bruno Nagel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1_pt">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maron</surname>
            <given-names>Paulo Eduardo Goulart</given-names>
          </name>
          <xref ref-type="aff" rid="aff2_pt">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vedovato</surname>
            <given-names>Bruno C&#xE9;sar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1_pt">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barrese</surname>
            <given-names>Tomas Zecchini</given-names>
          </name>
          <xref ref-type="aff" rid="aff2_pt">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>Roni de Carvalho</given-names>
          </name>
          <xref ref-type="aff" rid="aff2_pt">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Perez</surname>
            <given-names>Marjo Deninson Cardenuto</given-names>
          </name>
          <xref ref-type="aff" rid="aff2_pt">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1_pt"><label>1</label>Faculdade de Ci&#xEA;ncias M&#xE9;dicas, Santa Casa de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasil.</aff>
      <aff id="aff2_pt"><label>2</label>Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasil.</aff>
      <author-notes>
        <corresp id="c01_pt">Autor correspondente: Bruno Nagel Calado &#x2212; Santa Casa de S&#xE3;o Paulo, Rua Dr. Ces&#xE1;rio Motta Jr, 112 &#x2212; Vila Buarque &#x2212; CEP: 01221-020 &#x2212; S&#xE3;o Paulo, SP, Brasil &#x2212; Tel.: (11) 2176-7000 &#x2212; E-mail: caladobnc@gmail.com</corresp>
      </author-notes>
      <abstract>
        <p>O carcinoma de c&#xE9;lulas pequenas da bexiga urin&#xE1;ria &#xE9; um tumor extremamente agressivo e raro. Apesar desses tumores terem como s&#xED;tio principal o pulm&#xE3;o, existem diversos relatos de carcinoma de pequenas c&#xE9;lulas extrapulmonares. Pela baixa frequ&#xEA;ncia, ainda n&#xE3;o existe um tratamento bem estabelecido para essa neoplasia. Relatamos o caso de um homem de 61 anos de idade com carcinoma de c&#xE9;lulas pequenas da bexiga urin&#xE1;ria que foi submetido &#xE0; quimioterapia neoadjuvante seguida de cistectomia radical. Fazemos ainda revis&#xE3;o na literatura em busca dos m&#xE9;todos de maior sucesso para o tratamento.</p>
      </abstract>
      <kwd-group>
        <kwd>Neoplasias da bexiga urin&#xE1;ria/quimioterapia</kwd>
        <kwd>Carcinoma de c&#xE9;lulas pequenas/quimioterapia</kwd>
        <kwd>Cistectomia/m&#xE9;todos</kwd>
        <kwd>Relatos de casos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>INTRODU&#xC7;&#xC3;O</title>
        <p>O carcinoma de c&#xE9;lulas pequenas da bexiga &#xE9; um subtipo histol&#xF3;gico muito raro e agressivo, correspondendo a menos de 1% de todos os tumores de bexiga.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup>Sua abordagem torna-se desafiadora, pois se apresenta da mesma forma que outros tipos histol&#xF3;gicos mais frequentes, por&#xE9;m com alto poder metast&#xE1;tico. O diagn&#xF3;stico exige suspei&#xE7;&#xE3;o e precis&#xE3;o do patologista na an&#xE1;lise dos fragmentos de ressec&#xE7;&#xE3;o transuretral (RTU) de bexiga. O r&#xE1;pido tratamento multimodal, incluindo cistectomia radical, quimioterapia e radioterapia, deve ser institu&#xED;do o mais precocemente poss&#xED;vel, para haver chance de cura e melhora da sobrevida.<sup>(<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>)</sup>Esse tipo de carcinoma apresenta met&#xE1;stase e tem progn&#xF3;stico ruim.</p>
        <p>Neste artigo, relatamos o caso de um paciente do sexo masculino com carcinoma de c&#xE9;lulas pequenas de bexiga e sua evolu&#xE7;&#xE3;o, assim como buscamos trazer o que h&#xE1; de mais atual no manejo desse tumor que, por sua extrema raridade, n&#xE3;o apresenta consenso para o tratamento na literatura mundial.</p>
      </sec>
      <sec>
        <title>RELATO DE CASO</title>
        <p>Paciente JHC, masculino, 61 anos de idade, procurou servi&#xE7;o m&#xE9;dico com queixa de hemat&#xFA;ria e dor hipog&#xE1;strica h&#xE1; um ano. Evidenciada tumora&#xE7;&#xE3;o intravesical em ultrassonografia do aparelho urin&#xE1;rio, foi submetido a RTU de bexiga, cujo laudo foi conclusivo para carcinoma de c&#xE9;lulas pequenas de bexiga. Frente a esse diagn&#xF3;stico, a equipe que o acompanhava optou por realizar quimioterapia (recebeu quatro sess&#xF5;es de cisplatina, gencitabina e paclitaxel) (<xref ref-type="fig" rid="f01_pt">Figura 1</xref>).</p>
        <p>
<fig id="f01_pt" orientation="portrait" position="float"><label>Figura 1</label><caption><title>Presen&#xE7;a de m&#xFA;ltiplas mitoses no campo, n&#xFA;cleos em sal e pimenta</title></caption><graphic xlink:href="1679-4508-eins-13-1-114-gf01-pt"/></fig>
</p>
        <p>Ao ser encaminhado ao nosso servi&#xE7;o, foi submetido &#xE0; tomografia (TC) de t&#xF3;rax e abdome, a qual mostrou neoplasia de 6,2x6,0x5,5cm em parede anterolateral esquerda da bexiga, com sugestiva invas&#xE3;o de uretra prost&#xE1;tica. Acometimento linfonodal estava ausente, bem como les&#xF5;es metast&#xE1;ticas em outros s&#xED;tios.</p>
        <p>Foi, ent&#xE3;o, submetido &#xE0; cistectomia radical, com deriva&#xE7;&#xE3;o ileal &#xE0; Bricker, procedimento realizado sem intercorr&#xEA;ncias, com dura&#xE7;&#xE3;o total de 5 horas, sem necessidade de transfus&#xE3;o sangu&#xED;nea. Importante ressaltar que o tempo da &#xFA;ltima quimioterapia para a cirurgia foi de 2 meses.</p>
        <p>O laudo anatomopatol&#xF3;gico da pe&#xE7;a cir&#xFA;rgica comprovou carcinoma de c&#xE9;lulas pequenas de bexiga com extens&#xE3;o extravesical, infiltra&#xE7;&#xE3;o perineural e vascular presentes, comprometimento de um linfonodo (obturat&#xF3;rio esquerdo) em 16 dissecados. Margens livres. Estadiamento final T3bN1.</p>
        <p>No p&#xF3;s-operat&#xF3;rio apresentou pneumonia, sendo submetido a antibioticoterapia e recebendo alta hospitalar 29 dias ap&#xF3;s a cirurgia. N&#xE3;o houve intercorr&#xEA;ncia cir&#xFA;rgica. Foi encaminhado &#xE0; Oncologia para discuss&#xE3;o de tratamento adjuvante, que n&#xE3;o foi iniciado, pois o paciente faleceu 4 meses ap&#xF3;s a cirurgia devido a tromboembolismo pulmonar (<xref ref-type="fig" rid="f02_pt">Figura 2</xref>).</p>
        <p>
<fig id="f02_pt" orientation="portrait" position="float"><label>Figura 2</label><caption><title>Panorama geral do tumor</title></caption><graphic xlink:href="1679-4508-eins-13-1-114-gf02-pt"/></fig>
</p>
      </sec>
      <sec>
        <title>DISCUSS&#xC3;O</title>
        <p>O primeiro relato de carcinoma de c&#xE9;lulas pequenas de bexiga foi feito em 1981 por Cramer et al. Desde ent&#xE3;o, foram registrados aproximadamente 600 casos na literatura mundial.<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>&#xC9; caracterizado por sua alta agressividade e mau progn&#xF3;stico, bem como pelo desenvolvimento de doen&#xE7;a metast&#xE1;tica em cerca de 67% dos pacientes.<sup>(<xref rid="B3" ref-type="bibr">3</xref>)</sup>
</p>
        <p>O carcinoma de c&#xE9;lulas pequenas da bexiga urin&#xE1;ria costuma atingir pessoas da mesma idade, sexo e apresentar os mesmos sintomas e morfologia do carcinoma urotelial. Por isso, &#xE9; um desafio diagn&#xF3;stico, dependendo apenas da habilidade do patologista em diferenci&#xE1;-lo de carcinoma urotelial, que, al&#xE9;m dos fatores j&#xE1; citados, apresenta o mesmo aspecto radiol&#xF3;gico do carcinoma de c&#xE9;lulas pequenas de bexiga. N&#xE3;o h&#xE1; consenso quanto ao tratamento, por se tratar de patologia incomum. Assim, recomenda&#xE7;&#xF5;es s&#xE3;o baseadas em estudos retrospectivos, relatos de caso individuais e protocolos para carcinoma de c&#xE9;lulas pequenas de pulm&#xE3;o.</p>
        <p>Frequentemente, apresenta-se com histologia mista.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup>Estudos moleculares mostram origem comum entre o carcinoma de c&#xE9;lulas pequenas de bexiga e o carcinoma urotelial, quando coexistentes. No entanto, seu manejo deve ser diferente, pois, frequentemente, apresenta met&#xE1;stases e tem progn&#xF3;stico ruim. O diagn&#xF3;stico anatomopatol&#xF3;gico desse tipo de tumor &#xE9; desafiador e exige do patologista o uso de t&#xE9;cnicas de imuno-histoqu&#xED;mica para a confirma&#xE7;&#xE3;o histol&#xF3;gica. Como s&#xE3;o histologicamente id&#xEA;nticos, no diagn&#xF3;stico de carcinoma de c&#xE9;lulas pequenas de bexiga &#xE9; utilizada a padroniza&#xE7;&#xE3;o da Organiza&#xE7;&#xE3;o Mundial da Sa&#xFA;de para carcinoma de c&#xE9;lulas pequenas de pulm&#xE3;o, composta dos seguintes crit&#xE9;rios: presen&#xE7;a de grupos de c&#xE9;lulas pequenas com citoplasma escasso, poucas organelas, cromatina em &#x201C;sal e pimenta&#x201D;, e alta taxa de mitoses (&gt;10 mitoses/10 campos de alto poder).<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
        <p>Na imuno-histoqu&#xED;mica, esses tumores expressam muita enolase neuroespec&#xED;fica, cromogranina, sinaptofisina e N-CAM (CD-56). A presen&#xE7;a de um ou mais marcadores permite estabelecer o diagn&#xF3;stico de tumor neuroend&#xF3;crino. O estadiamento patol&#xF3;gico &#xE9; feito com base no consenso para carcinoma urotelial de bexiga (<xref ref-type="fig" rid="f03_pt">Figura 3</xref>).<sup>(<xref rid="B4" ref-type="bibr">4</xref>)</sup>
</p>
        <p>
<fig id="f03_pt" orientation="portrait" position="float"><label>Figura 3</label><caption><title>Marcador CD-56, que caracteriza tumores neuroend&#xF3;crinos</title></caption><graphic xlink:href="1679-4508-eins-13-1-114-gf03-pt"/></fig>
</p>
        <p>Terapias isoladas &#x2212; seja a RTU, a cistectomia parcial ou a radioterapia &#x2212; apresentam benef&#xED;cio apenas em casos especiais de doen&#xE7;a em est&#xE1;gio inicial. Cistectomia radical &#xE9; considerada o melhor m&#xE9;todo para remover o carcinoma de c&#xE9;lulas pequenas de bexiga completamente, mas acredita-se que ela sozinha s&#xF3; altera a sobrevida em tumores de est&#xE1;gios I e II.<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup>Cheng et al. revisaram 64 casos e conclu&#xED;ram que, em pacientes submetidos &#xE0; cirurgia radical comparados &#xE0;queles tratados com terapia combinada (seja apenas quimioterapia e radioterapia ou ambas em adjuv&#xE2;ncia), n&#xE3;o houve aumento da sobrevida.<sup>(<xref rid="B7" ref-type="bibr">7</xref>)</sup>Em contrapartida, quimioterapia adjuvante &#xE0; cistectomia radical resultou em progn&#xF3;stico favor&#xE1;vel em outros estudos, incluindo meta-an&#xE1;lises.<sup>(<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>)</sup>
</p>
        <p>Outra alternativa &#xE9; a quimioterapia neoadjuvante, recomendada pelo<italic>MDAnderson Cancer Center</italic>, o qual relatou sobrevida de 5 anos sem doen&#xE7;a em 36% do grupo submetido &#xE0; cistectomia radical isoladamente e de 78% no grupo submetido &#xE0; quimioterapia neoadjuvante &#xE0; cirurgia.<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup>De maneira semelhante, a radioterapia neoadjuvante tamb&#xE9;m mostrou-se eficiente.</p>
        <p>Por outro lado, um grupo canadense tratou dez pacientes com les&#xF5;es pT3-T4, N0 com quimioradioterapia, obtendo remiss&#xE3;o completa em nove deles. A taxa de sobrevida desse grupo no per&#xED;odo de 2 anos foi de 70% e, em 5 anos, de 44%.<sup>(<xref rid="B10" ref-type="bibr">10</xref>)</sup>Outra s&#xE9;rie na mesma linha relatou quatro pacientes tratados com quimioterapia seguida de radioterapia que sobreviveram de 27 a 60 meses. A vantagem desse tratamento &#xE9; a preserva&#xE7;&#xE3;o do &#xF3;rg&#xE3;o. Portanto, trata-se de terapia menos invasiva quando comparada &#xE0; cirurgia radical, a qual est&#xE1; relacionada a importantes taxas de morbidade e mortalidade.<sup>(<xref rid="B11" ref-type="bibr">11</xref>)</sup>
</p>
        <p>Pacientes com doen&#xE7;a metast&#xE1;tica devem receber quimioterapia sistem&#xE1;tica, sendo os esquemas terap&#xEA;uticos mais comuns os baseados em platina (cisplatina e etoposida, carboplatina, etoposida e ciclofosfamida) (<xref ref-type="fig" rid="f02_pt">Figura 2</xref>).<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup>
</p>
      </sec>
      <sec>
        <title>CONCLUS&#xC3;O</title>
        <p>Por se tratar de doen&#xE7;a extremamente agressiva e rara, pouco se conhece da patog&#xEA;nese e da biologia molecular. H&#xE1; escassez de dados para abordagem ideal desse tipo de tumor, mostrando a import&#xE2;ncia de relatar tais casos e, desta forma, definir melhor os m&#xE9;todos de diagn&#xF3;stico e tratamento.</p>
      </sec>
    </body>
  </sub-article>
</article>
</pmc-articleset>
